Evidence-based management and treatment of high-risk individuals with pre-diabetes

Journal of the Korean Medical Association

Volumn 54, Issue 10, 2011, Pages 1020-1027

  Chun, Ki Hong ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Evidence based intervention; Impaired fasting glucose; Impaired glucose tolerance; Prediabetes state

Indexed keywords

GLUCOSE; METFORMIN;

ASIAN; DEVELOPING COUNTRY; DIET RESTRICTION; DIET THERAPY; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PREVALENCE; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; SOCIAL ASPECT;

EID: 80054879019     PISSN: 19758456     EISSN: None     Source Type: Journal    
DOI: 10.5124/jkma.2011.54.10.1020     Document Type: Review

References (48)

1. Statistics Korea. Annual report on the cause of death stati-stics 2010 [Internet]. Deajeon: Statistics Korea; 2011 [cited 2011 Sep 19]. Available from: http://kostat.go.kr.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007 [Internet]. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008 [cited 2011 Sep 19]. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf.
3. International Diabetes Federation. Diabetes atlas. 4th ed. Brussels: International Diabetes Federation; 2009.
4. The Ministry of Health and Welfare; Korea Centers for Disease Control and Prevention. Korea health statistics 2009: Korea National Health and Nutrition Examination Survey (KNHANESIV-3). Seoul: Korea Centers for Disease Control and Prevention; 2010.
5. Harris MI, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. In: Alberti K, DeFron-zo RA, Keen H, Zimmet P, editors. International textbook of diabets mellitus. London: John Wiley & Sons; 1997. p. 3-18.
6. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H. HbA1c 5.7-6.4% and impaired fasting plasma glu-cose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lan-cet 2011;378:147-155.
7. Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Determinants of progression from impaired fas-ting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDI TION study, Denmark. Diabetologia 2008;51:249-257.
8. Alberti KG. Impaired glucose tolerance: fact or fiction. Diabet Med 1996;13(3 Suppl 2):S6-S8. (Pubitemid 26089977)
9. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six pros-pective studies. Diabetes 1997;46:701-710. (Pubitemid 27143390)
10. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759. (Pubitemid 46354366)
11. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-634.
12. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000;23:1619-1629.
13. Molitch ME, Fujimoto W, Hamman RF, Knowler WC; Diabetes Prevention Program Research Group. The diabetes prevention program and its global implications. J Am Soc Nephrol 2003;14(7 Suppl 2):S103-S107. (Pubitemid 36750502)
14. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996;19:1190-1193. (Pubitemid 26363430)
15. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980;1:1373-1376. (Pubitemid 10069461)
16. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989;12:464-474. (Pubitemid 19192108)
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553. (Pubitemid 28319935)
18. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999;42:793-801. (Pubitemid 29325068)
19. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350. (Pubitemid 32378388)
20. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544. (Pubitemid 27143412)
21. Koplan JP, Dietz WH. Caloric imbalance and public health policy. JAMA 1999;282:1579-1581. (Pubitemid 29504052)
22. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999;16:2-13. (Pubitemid 29147217)
23. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412. (Pubitemid 30609442)
24. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabe-tes 1997;46:1354-1359. (Pubitemid 27315286)
25. Niskanen L, Turpeinen A, Penttilä I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998;21:1861-1869. (Pubitemid 28478284)
26. Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyper-glycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1999;138(5 Pt 1):S353-S359. (Pubitemid 29523299)
27. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994;25:1157-1164. (Pubitemid 24164754)
28. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stro-ke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-68. (Pubitemid 26008297)
29. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other protentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-899. (Pubitemid 41094289)
30. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Risk factors pre-dicting lower extremity amputations in patients with NIDDM. Diabetes Care 1996;19:607-612. (Pubitemid 26181109)
31. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-268.
32. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):90-96. (Pubitemid 26011603)
33. Lee ET, Lee VS, Lu M, Lee JS, Russell D, Yeh J. Incidence of renal failure in NIDDM. The Oklahoma Indian Diabetes Study. Diabetes 1994;43:572-579. (Pubitemid 24096299)
34. Yokoyama H, Okudaira M, Otani T, Watanabe C, Takaike H, Miuira J, Yamada H, Mutou K, Satou A, Uchigata Y, Iwamoto Y. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care 1998;21:1080-1085. (Pubitemid 28368512)
35. Lee JH. Diabetic cardiac autonomic neuropathy: Symptoms, diagnosis and treatment. Korean Clinical Diabetes J 2010;11:195-198.
36. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23 Suppl 2:B21-B29. (Pubitemid 30185774)
37. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000;48:201-210. (Pubitemid 30232841)
38. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: 837-853.
39. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865.
40. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care 1999;22:1125-1136.
41. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care 2011;34 Suppl 1:S11-S61.
42. Korean Diabetes Association. Diabetes. Seoul: Korea Medicine; 2005.
43. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:1578-1584.
44. Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF; AusDiab Study Group. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care 2010;33:757-762.
45. Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Yamashita H, Ito H, Yoshimura Y, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010;53:419-428.
46. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated admi-nistrative data algorithm. Diabetes Care 2002;25:512-516. (Pubitemid 41103345)
47. Korea Centers for Disease Control and Prevention. Results of the secondary follow-up survey of the Anseong and Ansan cohorts. Seoul: Center for Genome Science; 2008.
48. Korea National Diabetes Program. KNDP participation organ [Internet]. Seoul: Korea Healthcare Technology R&D Project, Ministry of Health and Welfare; 2006 [cited 2011 Oct 4]. Available from: http://www.kndp.or.kr/project/ sub2-4.html.